Welcome to our dedicated page for Denali Therapeut SEC filings (Ticker: DNLI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Denali Therapeutics Inc. (DNLI) SEC filings page on Stock Titan provides access to the company’s publicly filed documents, including current reports on Form 8‑K and other disclosures incorporated by reference. Denali is a biotechnology and biopharmaceutical company based in South San Francisco, California, focused on product candidates engineered to cross the blood-brain barrier for neurodegenerative and lysosomal storage diseases.
Recent Form 8‑K filings referenced by the company include reports of quarterly financial results, such as second and third quarter 2025 results, and Regulation FD disclosures related to key regulatory milestones. For example, Denali filed 8‑K reports describing FDA acceptance and Priority Review of the Biologics License Application for tividenofusp alfa (DNL310) for Hunter syndrome (MPS II), and a subsequent extension of the Prescription Drug User Fee Act (PDUFA) target action date after submission of updated clinical pharmacology information classified as a Major Amendment.
Through this page, users can track how Denali reports material events such as clinical and regulatory updates, financial results and capital markets transactions, including public offerings of common stock and pre-funded warrants registered on Form S‑3. The filings complement the company’s press releases by providing formal regulatory context and references to exhibits such as earnings releases and detailed financial statements.
Stock Titan enhances access to these filings with tools designed to help readers quickly locate relevant 8‑K disclosures, review historical reporting patterns and connect SEC documents with related news about Denali’s TransportVehicle™ platform, pipeline programs and collaborations.
Denali Therapeutics Inc. (Nasdaq: DNLI) filed a Form 8-K to disclose a material regulatory milestone. On July 7, 2025, the company announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to Denali’s Biologics License Application (BLA) for tividenofusp alfa, its investigational therapy for Hunter syndrome (MPS II). The news was released via a press release attached as Exhibit 99.1. No financial figures, earnings data, or transactions were included in the filing. The Priority Review designation signals that the agency will evaluate the submission under an expedited pathway, underscoring the product’s potential importance for an underserved patient population. Other than routine exhibit listings and signature blocks, the 8-K contains no additional disclosures.